share_log

Wells Fargo Downgrades Kymera Therapeutics to Equal-Weight, Announces $26 Price Target

Benzinga ·  Dec 19, 2023 09:23

Wells Fargo analyst Derek Archila downgrades Kymera Therapeutics (NASDAQ:KYMR) from Overweight to Equal-Weight and announces $26 price target.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment